Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT04108195
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
- NCT04108195 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Focused
We haven't built an HCP commentary report on NCT04108195 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04108195 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab; Talquetamab; Teclistamab; Pomalidomide
- Arms
- Part 1: Dose Escalation · Experimental
- Part 2: Dose Expansion · Experimental
- Enrollment
- 290
- Primary outcomes
- Part 1: Number of Participants With Dose Limiting Toxicity (DLT)
- Part 1: Number of Participants With Dose Limiting Toxicity by Severity
- Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Part 2: Number of Participants With Adverse Events and SAEs by Severity
- Sponsor
- Janssen Research & Development, LLC
- Start
- Feb 21, 2020
- Primary completion
- Apr 7, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04108195 · updated Sep 25, 2026
Publications
linked from the registry- Rodriguez-Otero P, Morillo D, D'Souza A, Reece D, van de Donk N, Chari A, Dholaria B, Kortum KM, Mateos MV, Mckay JT, Rosinol L, Sureda A, Wasch R, Bhutani M, Weisel KC, Bahlis NJ, Vishwamitra D, Skerget S, Bakshi KK, Guo Y, Sun W, Goldberg JD, Stephenson T, Prior TJ, Vandenberk L, Lee S, Smit MD, Verona RI, Oriol A, Krishnan A. Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study. Blood Adv. 2026 Sep 2:bloodadvances.2026020648. doi: 10.1182/bloodadvances.2026020648. Online ahead of print. PubMed 42685673
- Chari A, van de Donk NWCJ, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosinol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi K, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit MD, Wasch R. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025 Dec 11;146(24):2902-2913. doi: 10.1182/blood.2025029360. PubMed 40983036
- Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonca M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393. PubMed 32956453